BIOMAT Database Logo BIOMAT Database Logo

Durvalumab plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-label, Nonrandomized, Phase II Clinical Trial. 2023

Shuchi Gulati, and McKenzie Crist, and Muhammed Kashif Riaz, and Vinita Takiar, and Maria Lehn, and Ilaina Monroe, and Sarah Palackdharry, and Nicky Kurtzweil, and Roman Jandarov, and Nusrat Harun, and Trisha M Wise-Draper
Department of Internal Medicine, Division of Hematology and Oncology, University of Cincinnati, Cincinnati, Ohio.

The efficacy of cetuximab is poor in metastatic head and neck squamous cell carcinoma (HNSCC). Cetuximab initiates natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity, with resultant recruitment of immune cells and suppression of antitumor immunity. We hypothesized that adding an immune-checkpoint inhibitor (ICI) could overcome this and lead to an enhanced antitumor response. A phase II study of cetuximab and durvalumab in metastatic HNSCC was conducted. Eligible patients had measurable disease. Patients who had received both cetuximab and an ICI were excluded. The primary endpoint was objective response rate (ORR) by RECIST 1.1 at 6 months. As of April 2022, 35 patients enrolled, of whom 33 received at least 1 dose of durvalumab and were included in the response analysis. Eleven patients (33%) had received prior platinum-based chemotherapy, 10 an ICI (30%), and 1 patient (3%) cetuximab. ORR was 39% (13/33) with a median duration of response of 8.6 months [95% confidence interval (CI): 6.5-16.8]. Median progression-free and overall survivals were 5.8 months (95% CI: 3.7-14.1) and 9.6 months (95% CI: 4.8-16.3), respectively. There were 16 grade 3 treatment-related adverse events (TRAE) and one grade 4 TRAE, with no treatment-related deaths. Overall and progression-free survival did not correlate with PD-L1 status. NK cell cytotoxic activity was increased by cetuximab and further increased with the addition of durvalumab in responders. The combination of cetuximab and durvalumab demonstrated durable activity with a tolerable safety profile in metastatic HNSCC and warrants further investigation.

UI MeSH Term Description Entries
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D006258 Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651) Cancer of Head and Neck,Head Cancer,Head Neoplasm,Head and Neck Cancer,Head and Neck Neoplasm,Neck Cancer,Neck Neoplasm,Neck Neoplasms,Neoplasms, Upper Aerodigestive Tract,UADT Neoplasm,Upper Aerodigestive Tract Neoplasm,Upper Aerodigestive Tract Neoplasms,Cancer of Head,Cancer of Neck,Cancer of the Head,Cancer of the Head and Neck,Cancer of the Neck,Head Neoplasms,Head, Neck Neoplasms,Neoplasms, Head,Neoplasms, Head and Neck,Neoplasms, Neck,UADT Neoplasms,Cancer, Head,Cancer, Neck,Cancers, Head,Cancers, Neck,Head Cancers,Neck Cancers,Neoplasm, Head,Neoplasm, Neck,Neoplasm, UADT,Neoplasms, UADT
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068818 Cetuximab A chimeric monoclonal antibody that functions as an ANTINEOPLASTIC AGENT through its binding to the EPIDERMAL GROWTH FACTOR RECEPTOR, where it prevents the binding and signaling action of cell growth and survival factors. C225,Erbitux,IMC C225,IMC-C225,MAb C225
D000077195 Squamous Cell Carcinoma of Head and Neck The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer. HNSCC,Head And Neck Squamous Cell Carcinomas,Hypopharyngeal Squamous Cell Carcinoma,Laryngeal Squamous Cell Carcinoma,Oral Cavity Squamous Cell Carcinoma,Oral Squamous Cell Carcinoma,Oral Squamous Cell Carcinomas,Oral Tongue Squamous Cell Carcinoma,Oropharyngeal Squamous Cell Carcinoma,Squamous Cell Carcinoma of Larynx,Squamous Cell Carcinoma of the Larynx,Squamous Cell Carcinoma of the Mouth,Squamous Cell Carcinoma of the Nasal Cavity,Carcinoma, Squamous Cell of Head and Neck,Head and Neck Squamous Cell Carcinoma,Squamous Cell Carcinoma of the Head and Neck,Squamous Cell Carcinoma, Head And Neck
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy

Related Publications

Shuchi Gulati, and McKenzie Crist, and Muhammed Kashif Riaz, and Vinita Takiar, and Maria Lehn, and Ilaina Monroe, and Sarah Palackdharry, and Nicky Kurtzweil, and Roman Jandarov, and Nusrat Harun, and Trisha M Wise-Draper
A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma.
May 2024, Clinical cancer research : an official journal of the American Association for Cancer Research,
Shuchi Gulati, and McKenzie Crist, and Muhammed Kashif Riaz, and Vinita Takiar, and Maria Lehn, and Ilaina Monroe, and Sarah Palackdharry, and Nicky Kurtzweil, and Roman Jandarov, and Nusrat Harun, and Trisha M Wise-Draper
Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study.
August 2018, The Lancet. Oncology,
Shuchi Gulati, and McKenzie Crist, and Muhammed Kashif Riaz, and Vinita Takiar, and Maria Lehn, and Ilaina Monroe, and Sarah Palackdharry, and Nicky Kurtzweil, and Roman Jandarov, and Nusrat Harun, and Trisha M Wise-Draper
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.
June 2021, The Lancet. Oncology,
Shuchi Gulati, and McKenzie Crist, and Muhammed Kashif Riaz, and Vinita Takiar, and Maria Lehn, and Ilaina Monroe, and Sarah Palackdharry, and Nicky Kurtzweil, and Roman Jandarov, and Nusrat Harun, and Trisha M Wise-Draper
Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
October 2023, Cancer research and treatment,
Shuchi Gulati, and McKenzie Crist, and Muhammed Kashif Riaz, and Vinita Takiar, and Maria Lehn, and Ilaina Monroe, and Sarah Palackdharry, and Nicky Kurtzweil, and Roman Jandarov, and Nusrat Harun, and Trisha M Wise-Draper
Phase Ib trial of IRX-2 plus durvalumab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
May 2024, Oral oncology,
Shuchi Gulati, and McKenzie Crist, and Muhammed Kashif Riaz, and Vinita Takiar, and Maria Lehn, and Ilaina Monroe, and Sarah Palackdharry, and Nicky Kurtzweil, and Roman Jandarov, and Nusrat Harun, and Trisha M Wise-Draper
Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study.
January 2019, Clinical cancer research : an official journal of the American Association for Cancer Research,
Shuchi Gulati, and McKenzie Crist, and Muhammed Kashif Riaz, and Vinita Takiar, and Maria Lehn, and Ilaina Monroe, and Sarah Palackdharry, and Nicky Kurtzweil, and Roman Jandarov, and Nusrat Harun, and Trisha M Wise-Draper
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.
July 2020, Annals of oncology : official journal of the European Society for Medical Oncology,
Shuchi Gulati, and McKenzie Crist, and Muhammed Kashif Riaz, and Vinita Takiar, and Maria Lehn, and Ilaina Monroe, and Sarah Palackdharry, and Nicky Kurtzweil, and Roman Jandarov, and Nusrat Harun, and Trisha M Wise-Draper
A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
May 2020, Cancer,
Shuchi Gulati, and McKenzie Crist, and Muhammed Kashif Riaz, and Vinita Takiar, and Maria Lehn, and Ilaina Monroe, and Sarah Palackdharry, and Nicky Kurtzweil, and Roman Jandarov, and Nusrat Harun, and Trisha M Wise-Draper
Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
July 2018, Oral oncology,
Shuchi Gulati, and McKenzie Crist, and Muhammed Kashif Riaz, and Vinita Takiar, and Maria Lehn, and Ilaina Monroe, and Sarah Palackdharry, and Nicky Kurtzweil, and Roman Jandarov, and Nusrat Harun, and Trisha M Wise-Draper
Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
November 2016, BMC cancer,
Copied contents to your clipboard!